
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower net loss of $1.14 per share in 2Q25, compared to the original estimate of $1.22, indicating improved financial performance. The positive safety profile of its leading candidate, OKI-219, was highlighted, as it was well-tolerated across all dose levels with no severe adverse events reported. This combination of reduced losses and strong clinical trial results supports a constructive outlook on the company's potential to advance in the biopharmaceutical market.
Bears say
OnKure Therapeutics is projecting a significant net loss of $4.56 per share for the full year 2025, a slight improvement from a previous estimate of $4.75 per share, indicating ongoing challenges in achieving profitability. The company faces multiple risks, including potential negative clinical results from their lead asset, OKI-219, delays in advancing their pipeline candidates, and difficulties in obtaining timely regulatory approvals. Additionally, competition in the market and long-term dilution risk compound the uncertainties surrounding the company's financial outlook, presenting significant concerns for investors.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares